The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma
dc.contributor.author | Uysal, Ayşe | |
dc.contributor.author | Erkurt, Mehmet Ali | |
dc.contributor.author | Kuku, İrfan | |
dc.contributor.author | Kaya, Emin | |
dc.contributor.author | Berber, İlhami | |
dc.contributor.author | Sarıcı, Ahmet | |
dc.contributor.author | Biçim, Soykan | |
dc.date.accessioned | 2024-08-04T19:42:43Z | |
dc.date.available | 2024-08-04T19:42:43Z | |
dc.date.issued | 2023 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Aim: In this single-center, retrospective study, we aimed to evaluate the effect of CD34+ stem cell dose on hematologic recovery and long-term outcomes such as progression-free survival and overall survival after autologous stem cell transplantation (ASCT). Materials and Methods: In this study, 282 patients with MM, who underwent ASCT between January 2014 and October 2021 were evaluated. The patients were divided into 2 groups according to the infused cell dose. Patients who received ?5x106/kg CD34+ cells were defined as group A. Patients who received >5x106/kg CD34+ cells were group B. The outcome of ASCT including the time of neutrophil/platelet engraftment, febrile neutropenia status, transplant-related mortality (TRM) at 100 days, duration of hospital- ization and survival status were examined in both groups. Results: There were 118 (41.8%) patients in group A and 164 patients (58.2%) in group B. The median neutrophil engraftment was 12 (7-26) days in A group, 11 (6-28) days in B group. The median platelet engraftment was 12 (6-40) and 11 (6-29) days in group B. There were statically significant different in both group for neutrophil and platelet engraftment time (p=.001 and .002, respectively). The median hospitalization time was 16 (10-53) days and 15 (6-83) days in group A and B, respectively. The hospitalization time was statistically significantly different in two groups (p<.012). The mean OS was 53.1±4.2 months in group A and 58.2±3.5 in group B which was not statistically significant difference (p=.841). The mean PFS was 11.8±1.3 months in group A and 19.1±1.4 months in group B which was statistically significant difference in 2 groups (p<0.001). Conclusion: Infusion of >5x106/kg CD34+ stem cells (median dose 9,6 x106/kg) may have a favorable effect on short-term outcomes of transplantation, including short-term neutrophil engraftment, short-term platelet engraftment, and short-term hospitalization. Additionally, progression-free survival may be positively affected by high dose, but upper limit should be defined by new study. | en_US |
dc.identifier.doi | 10.5455/annalsmedres.2022.12.378 | |
dc.identifier.endpage | 336 | en_US |
dc.identifier.issn | 2636-7688 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 331 | en_US |
dc.identifier.trdizinid | 1162353 | en_US |
dc.identifier.uri | https://doi.org/10.5455/annalsmedres.2022.12.378 | |
dc.identifier.uri | https://search.trdizin.gov.tr/yayin/detay/1162353 | |
dc.identifier.uri | https://hdl.handle.net/11616/88608 | |
dc.identifier.volume | 30 | en_US |
dc.indekslendigikaynak | TR-Dizin | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Annals of Medical Research | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma | en_US |
dc.type | Article | en_US |